LENZ Therapeutics (NASDAQ:LENZ) Given Outperform Rating at Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a report published on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Several other equities analysts have also commented on LENZ. SVB Leerink started coverage on LENZ Therapeutics in a report on Monday. They issued an outperform rating and a $32.00 target price on the stock. Citigroup began coverage on LENZ Therapeutics in a report on Wednesday, April 10th. They set a buy rating and a $34.00 price objective on the stock. Piper Sandler began coverage on LENZ Therapeutics in a report on Wednesday, March 27th. They set an overweight rating and a $28.00 price objective on the stock. Finally, William Blair began coverage on shares of LENZ Therapeutics in a research note on Monday. They set an outperform rating for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, LENZ Therapeutics presently has a consensus rating of Buy and an average target price of $31.33.

LENZ Therapeutics Stock Performance

Shares of NASDAQ LENZ opened at $17.49 on Monday. The firm has a market capitalization of $145.52 million, a PE ratio of -1.12 and a beta of 0.20. LENZ Therapeutics has a 12-month low of $14.07 and a 12-month high of $29.82.

Insider Activity

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was acquired at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the purchase, the director now directly owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.